Skip to main content

Table 1 Baseline characteristics of patients with hepatitis C virus (HCV) infection who were treated with PegIFN-α-2a plus ribavirin (Group 1) and those who were treated with PegIFN-α-2b plus ribavirin (Group 2)

From: Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C

Characteristics Group 1 (N = 55) Group 2 (N = 26) Statistic Value P-value
Sex (n, %)    0.045 b 0.831
 Female 31 (56.4) 14 (53.8)   
 Male 24 (43.6) 12 (46.2)   
Age at recruitment (years) 52.8 ± 12.2 55.0 ± 11.5 0.747 c 0.457
Body weight (kg) 65.7 ± 12.1 63.8 ± 12.8 0.644 c 0.521
Alcohol use disorder (n, %) 7 (12.7) 1 (3.8) 1.564 d 0.426
Number of physical illness 2.8 ± 1.8 2.4 ± 1.2 1.287 c 0.203
α-fetoprotein level (ng/mL) 10.6 ± 15.8 7.6 ± 5.9 0.903 c 0.369
Genotype of HCV a    0.104 b 0.747
 1 27 (50) 14 (53.8)   
 Non-1 27 (50) 12 (46.2)   
PegIFN-α-2a dose (mcg/week) 175.1 ± 14.2 - N/A N/A
PegIFN-α-2b dose (mcg/week) - 94.8 ± 12.4 N/A N/A
Ribavirin dose (mg/day) 1048.2 ± 164.5 958.3 ± 131.6 2.357 c 0.021*
HADS-Depression score 5.0 ± 3.8 4.0 ± 3.1 1.008 e 0.314
Depressive state (n, %) 14 (25.5) 3 (11.5) 2.062 d 0.242
HADS-Anxiety score 6.6 ± 4.1 6.7 ± 4.7 0.193 e 0.847
Anxiety state (n, %) 21 (38.2) 6 (23.1) 1.813 b 0.214
  1. Note: Data is expressed by n (%) or mean ± SD
  2. PegIFN-α-2a: Pegylated interferon-α-2a, PegIFN-α-2b: Peginterferon-α-2b, HADS: the Hospital Anxiety and Depression Scale, N/A: non-applicable
  3. *p < 0.05
  4. aHCV genotyping of one patient in Group 1 was undetermined
  5. bChi-square test (degrees of freedom = 1)
  6. cFisher’s exact test
  7. dt-test (degrees of freedom = 79)
  8. eMann–Whitney U-test